SABCS 2024
Novel Humanized LIV-1 Antibody Based ADCs Site-Specifically Conjugated with Topoisomerase I Inhibitor Payloads Displayed Significantly Higher Anti-tumor Activities than MMAE based ADCs in TNBC Tumor Models
